In early March the company released a presentation indicating...

In early March the company released a presentation indicating two things:

- a new commercial relationship with a Phylomer class; and

- "a transaction" with a big pharma

We have seen the first (Dynamic Microbials - anti prion/virus/bacteria application of Phylomers).

We are waiting on the second. We have until early September before we are "overdue".

Small molecules, of the Phylomer type, are attracting renewed interest by biotech's. Genentech (the first biotech) has announced a new programme of investment.

In my personal view, the Phylomer framework is "simply brilliant". I believe Dr Watt et al have invented an approach that will overcome the huge difficulties (in terms of biological activity) that small molecule drugs have encountered, to date.

Phylomers are certainly "beyond antibodies". In my view Phylomers are the next step beyond RNAi. There are about 7000 drugable genes. There are, possibly, 10x more drugable proteins - with Phylomers.